Warning Letter Roundup & Recap – Oct. 4, 2016
FDA finds approval and marketing violations at a Texas dermatology device firm; QS and approval violations noted at a New Jersey maker of collagen-based surgical tools. FDA released warning letters to two device companies this week. Plus: check out Medtech Insight's new FDA Warning Letters Data Tracker.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.